HIV News: NIAID Study Describes Successful Treatment Regimen for Person with Multidrug-Resistant HIV

Thursday, January 16, 2025 NIAID Study Describes Successful Treatment Regimen for Person with Multidrug-Resistant HIV Transmission electron micrograph of HIV-1 virus particles (red) budding and replicating from a segment of a cell (blue). Credit: NIAID A NIAID study describes the successful treatment of a person with multidrug-resistant HIV with a regimen including the monoclonal antibody UB-421 (semzuvolemab) and lenacapavir-based ART. Levels of HIV in the person's blood rapidly decreased within two weeks of beginning the regimen and were below the detection limit after one year of treatment. The study is highlighted in NIAID Now. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107